TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26363701
Drug: Cognitive Behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioural Therapy (CBT) plus standard care (medication and contact with the local clinical team)
Study: 24548978
Drug: Capsule formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule formulation of lenvatinib (10 mg)
Study: 24548978
Drug: High-fat meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fat meal with capsule formulation of lenvatinib (10 mg)
Study: 24548978
Drug: Tablet formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet formulation of lenvatinib (10 mg)
Study: 7859889
Drug: Mean total
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mean total urinary iodine excretion (UIT)
Study: 30974479
Drug: Manual Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual Therapy and Exercise (MT-EX)
Study: 21446235
Drug: Hood nebulization
Normalized name: HOODIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hood nebulization of 0.30 mg/kg salbutamol
Study: 21446235
Drug: Mask nebulization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mask nebulization of 0.30 mg/kg salbutamol
Study: 12768947
Drug: 2-weekly intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-weekly intramuscular penicillin
Study: 9740926
Drug: Brompheniramine 12
Normalized name: BROMPHENIRAMINE 12MG/PSEUDOEPHEDRINE 120MG CAP,SA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brompheniramine 12 mg
Study: 6137325
Drug: Clopamide, 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopamide, 5 mg/day
Study: 6137325
Drug: Indapamide, 2.5
Normalized name: Indapamide, 2.5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indapamide, 2.5 mg/day
Study: 6137325
Drug: Chlorthalidone, 100
Normalized name: Chlorthalidone, 100 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone, 100 mg/day + beta-blocker (propranolol or atenolol)
Study: 6137325
Drug: Clopamide +
Normalized name: clopamide
DrugBank: Clopamide (DB13792)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopamide + beta-blocker (pindolol, 10 mg/day)
Study: 11220982
Drug: Sildenafil 25
Normalized name: sildenafil 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 25 mg
Study: 30261903
Drug: Sildenafil 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 75 mg
Study: 30261903
Drug: Sildenafil (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (3 times daily from 3 days before planned delivery until actual delivery)
Study: 29603705
Drug: Articaine buccal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Articaine buccal infiltration
Study: 23054175
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural treatment (CBT) added to managed care
Study: 8454328
Drug: CMR vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMR vaccine 60 micrograms
Study: 8454328
Drug: CMR vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMR vaccine 120 micrograms
Study: 8454328
Drug: CMR vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMR vaccine 30 micrograms
Study: 16317122
Drug: Dietary cholesterol
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary cholesterol from 3 large eggs (EGG) daily
Study: 10804324
Drug: Apo(a) phenotypes
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Apo(a) phenotypes determined using 4‐15% sodium dodecyl sulfate polyacrylamide gel electrophoresis followed by immunoblotting
Study: 6341843
Drug: Standard (control)
Normalized name: Stangard
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard (control) therapy
Study: 24811601
Drug: PRT-201 (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRT-201 (high dose)
Study: 24811601
Drug: PRT-201 (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRT-201 (low dose)
Study: 1617983
Drug: N-acetylcysteine 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine 150 mg/kg as a loading dose and then 20 mg/kg/hr for 6 days
Study: 27336868
Drug: Lornoxicam with
Normalized name: lornoxicam
DrugBank: Lornoxicam (DB06725)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lornoxicam with 5 mg droperidol
Study: 27336868
Drug: Lornoxicam with
Normalized name: lornoxicam
DrugBank: Lornoxicam (DB06725)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lornoxicam with 8 mg ondansetron
Study: 27336868
Drug: Lornoxicam with
Normalized name: lornoxicam
DrugBank: Lornoxicam (DB06725)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lornoxicam with 6 mg granisetron
Study: 23015161
Drug: Warfarin dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin dosing algorithm
Study: 20460558
Drug: Beers criteria
Normalized name: BEER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beers criteria drug
Study: 2679331
Drug: Intrathecal diamorphine
Normalized name: Diamorphine
DrugBank: Diamorphine (DB01452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal diamorphine 0.25 mg
Study: 68703
Drug: Topical nasal
Normalized name: Nasal Inhalant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical nasal spray
Study: 68703
Drug: Oral syrup
Normalized name: Cola Oral Syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral syrup formulations
Study: 19863501
Drug: Prednisolone (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (initial dose 0.5‐0.8 mg kg(‐1) daily for 2 weeks followed by placebo for 4 weeks)
Study: 19863501
Drug: Ciclosporin (2.7‐4.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciclosporin (2.7‐4.0 mg kg(‐1) daily for 6 weeks)
Study: 1671113
Drug: nifedipine 10
Normalized name: nifedipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: nifedipine 10 mg with grapefruit juice
Study: 1671113
Drug: nifedipine 10
Normalized name: nifedipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: nifedipine 10 mg with water
Study: 1671113
Drug: felodipine 5
Normalized name: felodipine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: felodipine 5 mg with orange juice
Study: 31691521
Drug: Fast-Track Treatment
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast-Track Treatment Initiation Counselling (FTIC)
Study: 23600368
Drug: Highest dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highest dose of rosuvastatin (40 mg/day)
Study: 24618208
Drug: Add-on-statin extended
Approvals — FDA: no, EMA: no, PMDA: no
Description: Add-on-statin extended release nicotinic acid (ER-NA)/laropiprant (1000/20 mg/day for the first 4 weeks followed by 2000/40 mg/day for the next 8 weeks)
Study: 1950641
Drug: Intranasally administered
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasally administered (DesGly9‐Arg8) vasopressin (DGAVP)
Study: 7028050
Drug: Ciclopiroxolamine cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciclopiroxolamine cream (1% concentration) applied for 21 days
Study: 7028050
Drug: Vehicle (placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle (placebo cream) applied for 21 days
Study: 29722071
Drug: Daily text
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily text messages with patient education material and treatment reminders
Study: 21239069
Drug: losartan (weight-adjusted
Approvals — FDA: no, EMA: no, PMDA: no
Description: losartan (weight-adjusted treatment)
Study: 18675344
Drug: Griseofulvin lyophilized
Normalized name: Griseofulvin
DrugBank: Griseofulvin (DB00400)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Griseofulvin lyophilized dry emulsion (LDE) tablet (125 mg) without water
Study: 18675344
Drug: Immediate release
Normalized name: Namenda, immediate release oral kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate release (IR) tablet
Study: 15982992
Drug: alpha-lactalbumin protein
Normalized name: alpha-lactalbumin (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha-lactalbumin protein administration
Study: 1669137
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous infusion of streptokinase (250,000 IU initial dose, 100,000 IU/h maintenance)
Study: 1669137
Drug: Intermittent administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent administration of streptokinase (500,000 IU initial dose, 250,000 IU every 12 h)
Study: 1669137
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous infusion of streptokinase
Study: 1669137
Drug: Intermittent administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent administration of streptokinase
Study: 6120902
Drug: 0.1 g
Normalized name: BIOTIN 0.1 g in 100 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 g atenolol
Study: 27888045
Drug: Tiotropium (18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium (18 μg single dose)
Study: 23292159
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg nebulized inhalative epinephrine
Study: 23292159
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg nebulized inhalative epinephrine
Study: 23292159
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg intramuscular epinephrine
Study: 11099872
Drug: Tibolone 2.5
Normalized name: tibolone 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone 2.5 mg per day
Study: 1059540
Drug: 9% stannous-fluoride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9% stannous-fluoride treatment on right incisors before extraction
Study: 31130270
Drug: Buteyko breathing
Normalized name: cetylpyridinium chloride Mouthwash [Breath-Away]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buteyko breathing technique in conjunction with medical management (nasal steroid)
Study: 11029565
Drug: Lidocaine inhalation
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine inhalation (1%, 4%, and 10% concentrations, total doses of 0.5, 2.0, and 5.0 mg kg‐1)
Study: 11029565
Drug: Lidocaine inhalation
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine inhalation (1%, 4%, and 10% concentrations)
Study: 11029565
Drug: Lidocaine inhalation
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine inhalation (4% and 10% concentrations)
Study: 11029565
Drug: Lidocaine inhalation
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine inhalation (4% solution)
Study: 30463813
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg atorvastatin
Study: 15167308
Drug: Soy protein
Normalized name: Soy Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy protein with 96 mg isoflavones/day
Study: 15167308
Drug: Soy with
Normalized name: pediatric nutrition, soy with iron, lactose free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy with 52 mg isoflavones/day
Study: 15167308
Drug: Soy without
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy without isoflavones (< 4 mg isoflavones/day)
Study: 9679792
Drug: Minidose warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minidose warfarin (1.25 mg/d)
Study: 9679792
Drug: Warfarin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin plus aspirin (1.25 mg/d + 300 mg/d)
Study: 10068745
Drug: bismuth‐metronidazole‐amoxicillin‐ranitidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: bismuth‐metronidazole‐amoxicillin‐ranitidine
Study: 2652906
Drug: Nisoldipine (calcium-channel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nisoldipine (calcium-channel blocker)
Study: 319713
Drug: Oral atropine
Normalized name: atropine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral atropine sulfate 0.5 mg four times a day
Study: 25416496
Drug: Cuscuta planiflora
Normalized name: Cuscuta reflexa extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cuscuta planiflora capsules (500 mg) and conventional drugs
Study: 25416496
Drug: Conventional drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional drugs only
Study: 20516268
Drug: 800 IU
Normalized name: Vitamin E 800 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 IU vitamin D(3) daily for 6 months
Study: 20516268
Drug: 2000 mg
Normalized name: bran 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2000 mg elemental calcium daily for 6 months
Study: 8580278
Drug: Budesonide enema
Normalized name: budesonide Enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide enema (2 mg/100 mL)
Study: 9348757
Drug: Psychoactive drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychoactive drugs (e.g., benzodiazepines)
Study: 8281985
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg acetylsalicylic acid (ASA) infused intravenously
Study: 8281985
Drug: ASA infusion
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ASA infusion
Study: 24665827
Drug: PF4/H antibody-positive
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF4/H antibody-positive patients
Study: 18356758
Drug: Family-based cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-based cognitive-behavioral therapy (CBT)
Study: 16008322
Drug: Prostina (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostina (2 capsules twice daily for 12 weeks)
Study: 16008322
Drug: Terazosin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terazosin (2 mg at bedtime for 12 weeks)
Study: 12466730
Drug: Hydralazine bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydralazine bolus injection (n = 44)
Study: 10367320
Drug: Avonex 6.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avonex 6.0 MUI (30 micrograms) administered by intramuscular injection weekly
Study: 7747534
Drug: Miconazole-hydrocortisone cream
Normalized name: hydrocortisone / miconazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miconazole-hydrocortisone cream and ketoconazole shampoo (Group A)
Study: 7747534
Drug: Hydrocortisone cream
Normalized name: Hydrocortisone Cream
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone cream and placebo shampoo (Group B)
Study: 2157982
Drug: 33B3.1 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: 33B3.1 (10 mg per day)
Study: 393377
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment only (control group)
Study: 30660472
Drug: Clinical risk
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical risk model (Karnofsky performance status, radiation therapy)
Study: 25992877
Drug: Tight intraoperative
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tight intraoperative glucose control with hyperinsulinemic-normoglycemic clamp (target blood glucose, 80 to 110 mg/dl)
Study: 23351820
Drug: Synchronous clopidogrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synchronous clopidogrel + EC aspirin (81 mg) + EC omeprazole (40 mg)
Study: 11093435
Drug: Intramuscular methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intramuscular methotrexate (MTX)
Study: 3495259
Drug: Domperidone 30
Normalized name: domperidone 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone 30 mg (D)
Study: 20226302
Drug: Desloratadine 5
Normalized name: desloratadine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desloratadine 5 mg, 10 mg, 20 mg
Study: 20226302
Drug: Levocetirizine 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levocetirizine 20 mg
Study: 20226302
Drug: Desloratadine 20
Normalized name: Desloratadine
DrugBank: Desloratadine (DB00967)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desloratadine 20 mg
Study: 20226302
Drug: Increasing antihistamine
Normalized name: Ahist Antihistamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increasing antihistamine doses
Study: 19083400
Drug: Hydrogen-rich water
Normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrogen-rich water (900 mL/d for 8 weeks)
Study: 19083400
Drug: Placebo pure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pure water (900 mL/d for 8 weeks)
Study: 16650535
Drug: Endoscopic combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic combination therapy (n = 52)
Study: 10772522
Drug: Blunt dilator/cannula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blunt dilator/cannula treatment
Study: 1334825
Drug: 125I‐labeled soluble
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125I‐labeled soluble insulin
Study: 31607641
Drug: Second-line chemotherapy
Normalized name: Gallus gallus gizzard lining preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-line chemotherapy (overall)
Study: 28387882
Drug: Placebo (vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (vehicle preparation)
Study: 14728632
Drug: Alfacalcidol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfacalcidol (1 microg daily for 36 weeks)
Study: 7942728
Drug: Erythromycin ethylsuccinate
Normalized name: Erythromycin Ethylsuccinate
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin ethylsuccinate elixir (400 mg/5 ml per os every 8 h for three doses)
Study: 26185773
Drug: MOR103 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOR103 1.0 mg/kg
Study: 24534756
Drug: MOR103 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOR103 1.5 mg/kg
Study: 24534756
Drug: MOR103 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOR103 0.3 mg/kg
Study: 9350924
Drug: Thallium scintigraphy
Normalized name: thallium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thallium scintigraphy after 6 months of therapy
Study: 9350924
Drug: Exercise electrocardiography
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise electrocardiography after 6 months of therapy
Study: 20431041
Drug: Octreotide LAR
Normalized name: octreotide LAR 20 MG Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide LAR depot (up to 40 mg every 28+/‐5 days)
Study: 16169793
Drug: Heliox-driven nebulization
Normalized name: Helixate
DrugBank: Antihemophilic factor, human recombinant (DB00025)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heliox-driven nebulization of albuterol labeled with Tc-99m DTPA
Study: 16169793
Drug: Air-driven nebulization
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Air-driven nebulization of albuterol labeled with Tc-99m DTPA
Study: 10071149
Drug: Systemic prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic prednisolone treatment (group B)
Study: 7768760
Drug: Co-amoxiclav 3.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-amoxiclav 3.25 g single dose
Study: 7768760
Drug: Co-trimoxazole 960
Normalized name: CO
DrugBank: Carbon monoxide (DB11588)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-trimoxazole 960 mg bd for 7 days
Study: 1983433
Drug: Cloxazolam (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cloxazolam (4 mg/day)
Study: 1983433
Drug: Bromazepam (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromazepam (12 mg/day)
Study: 2183866
Drug: Paracetamol (4.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol (4.0 g daily)
Study: 24011514
Drug: NCB-02 (curcumin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NCB-02 (curcumin) enema plus oral 5-ASA
Study: 24011514
Drug: Placebo enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo enema plus oral 5-ASA
Study: 9602258
Drug: 5000 IU
Normalized name: D 5000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5000 IU rhEPO daily s.c.
Study: 31501293
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of conventional HF treatment
Study: 19464709
Drug: Pentoxifylline (PXF)
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline (PXF) 1200 mg daily for 12 months
Study: 16409425
Drug: 3-weekly regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-weekly regimen of gemcitabine (1000 mg/qm, days 1 and 8) and paclitaxel (175 mg/qm, day 1)
Study: 15281431
Drug: Colchicine 1
Normalized name: colchicine 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine 1 mg qd plus prednisone 10 mg qd
Study: 10632642
Drug: Alosetron 0.5
Normalized name: alosetron 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alosetron 0.5 mg b.d.
Study: 11284782
Drug: Alosetron 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alosetron 1.0 mg b.d.
Study: 11284782
Drug: Alosetron 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alosetron 2.0 mg b.d.
Study: 3567001
Drug: Aminophylline 670
Normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline 670 mg (high-dose)
Study: 3567001
Drug: Placebo (aerosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (aerosol and infusion)
Study: 24763840
Drug: Lignocaine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lignocaine (10 mL of 2% lignocaine with adrenaline 1:200,000)
Study: 24763840
Drug: Ropivacaine alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine alone (20 mL of 0.75% ropivacaine)
Study: 15979016
Drug: Spinal cord
Normalized name: BOS TAURUS SPINAL CORD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal cord stimulation (SCS) treatment
Study: 15790985
Drug: Salmeterol 50
Normalized name: FLUTICAS 100/SALMETEROL 50 INHL DISK 14
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol 50 microg twice daily
Study: 27258301
Drug: PRISE (5-6
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRISE (5-6 meals/day at 2.0 g/kg BW/day)
Study: 17576969
Drug: Morphine 1
Normalized name: morphine 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 1 mg ml(‐1)
Study: 17576969
Drug: Morphine with
Normalized name: opium alkaloids with morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine with ketamine 1 mg ml(‐1)
Study: 11713072
Drug: Intracameral saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracameral saline (0.5 ml sterile saline)
Study: 11713072
Drug: Intracameral lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracameral lidocaine (0.5 ml preservative-free 2%)
Study: 24480077
Drug: Minocycline (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline (200 mg/day)
Study: 2885505
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg Sb/kg per day for twenty days